NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions

Advanced Solid TumorsColorectal CancerNon Small Cell Lung CancerBiliary Tract Cancer

Interventions

DRUG

CAN04 (nadunolimab)

FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

DRUG

mFOLFOX

mFOLFOX/CAN04

DRUG

DTX

DTX/CAN04

DRUG

G/C

G/C/CAN04

Trial Locations (6)

Centre Georges François Leclerc, Dijon

Hospital Universitario 12 de Octubre, Madrid

Institut Bergonie, Bordeaux

Centre Eugene Marquis, Rennes

EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain

Hospital Universitari Vall D'Hebron, Barcelona